Metal-based antitumor compounds: beyond cisplatin
Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatm...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
2019
|
| Online Access: | http://hdl.handle.net/20.500.11937/74389 |